The company’s application is based on results from a late-stage study in which the drug was shown to reduce the rate of cognitive decline in patients with early Alzheimer’s by 27%, compared with a placebo.
Tag Archive for: Lecanemab
The U.S. Food and Drug Administration approved Eisai Co Ltd’s and Biogen Inc’s Alzheimer’s drug lecanemab for patients in the earliest stages of the mind-wasting disease, the agency said on Friday.
A letter published Wednesday in the NEJM links a stroke patient’s death to lecanemab. Eisai investigators respond.
The announcement comes as the company awaits the FDA’s decision for Biogen and Japanese partner Eisai Co’s Alzheimer’s drug lecanemab.
An influential drug pricing research group said Eisai Co. Ltd. and Biogen Inc.’s new Alzheimer’s disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies.
2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications.
Full data presented Tuesday afternoon from the Phase III Clarity AD trial show Eisai and Biogen’s lecanemab has a favorable safety profile in patients with Alzheimer’s disease.
One day ahead of a data presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Science reported a second patient death has been linked to Eisai and Biogen’s lecanemab.
The first big breakthrough in 30 years of Alzheimer’s research is providing momentum for clinical trials of “cocktail” treatments targeting the two hallmark proteins associated with the mind-robbing disease.
An investigator in the Phase III trial for Biogen and Eisai’s experimental Alzheimer’s drug lecanemab is attributing a patient’s death to the drug.
